NCT00985907 · REGISTRY CONDITION SEARCH

Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE1, PHASE2
Status at capture: TERMINATED
Registry last update: 2020-06-17

The median overall survival (OS) of relapsed/refractory multiple myeloma (MM) is less than nine months. However, phase II data with the proteasome inhibitor bortezomib (Velcade®) has been heartening, with 35% overall response rates and median survival of 16 months. In-vitro data has shown that this agent dramatically increases the sensitivity to chemotherapeutic agents. Liposomal doxorubicin (Doxil), melphalan, and bortezomib all have different mechanisms of action and toxicity profiles. Clinical studies employing two drug combinations with these agents in patients with refractory MM have found favorable efficacy (nearly no progression of disease) and tolerance data. Thus, the investigators are initiating a phase I/II study to examine the safety and efficacy of combining all three agents into the regimen DMV (Doxil® + melphalan + Velcade).

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Participants With Dose Limiting Toxicities (DLT) (Phase 1)

→

outcome · POSTED

Maximum Tolerated Dose (MTD) (Phase 1)

→

outcome · POSTED

Number of All Treatment-related Toxicities at the MTD (Phase 1)

→

outcome · POSTED

Overall Response Rate

→

outcome · POSTED

Time to Response (Phase 2)

→

outcome · POSTED

Progression-free Survival (Phase 2)

→

outcome · POSTED

Overall Survival (Phase 2)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: Disease Characteristics: 1. Patient previously diagnosed with multiple myeloma; Durie-Salmon Stage I, II, or III based on standard criteria 2. Progressive disease. For non-secretory multiple myeloma, progressive disease is defined as bone marrow biopsy with \> 25% increase in plasma cells or an absolute increase of at least 10% over prior known level. Alternatively, development of new or worsening of existing lytic bone lesions or soft tissue plasmacytomas, or hypercalcemia (serum calcium \>11.5 mg/dL), or relapse from complete response. Patient Characteristics: 1. 18 yrs or older 2. Patient has given voluntary written informed consent. 3. Unless post-menopausal or surgically sterilized, a female must be willing to use an acceptable method of birth control 4. Male patient must agree to use an acceptable method for contraception for the duration of the study. 5. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2. 6. Life expectancy is at least 3 months. 7. • Absolute Neutrophil Count (ANC) over 1,000/ul without the use of colony stimulating factors * Platelets over 50,000/ul without transfusion support 7 days * Bilirubin 2.0 mg/dl or less * aspartate aminotransferase (AST) 4 times or less upper limit normal Prior Therapy for Multiple Myeloma: Patients must have had at least 2 prior therapeutic regimens Exclusion Criteria: * Pregnant or breast feeding * History of allergic reaction to compounds containing boron or mannitol. * Active uncontrolled viral (including HIV), bacterial, or fungal infection. * Grade III or IV toxicity due to previous anti-neoplastic therapy * More than Grade 2 motor or sensory neuropathy * Myocardial infarction within 6 months of enrollment or New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled arrhythmias, or electrocardiographic evidence of acute ischemia. * For any patients whose lifetime cumulative doxorubicin dose exceeds 400mg/m2, patients with left ventricular ejection fraction (LVEF) less than 35% by multigated acquisition (MUGA) . * Concurrent administration of liposomal doxorubicin, melphalan, and bortezomib (single or two drug combinations of these are permissible) * Less than 3 weeks since most recent chemotherapy or concurrent chemotherapy * Use of corticosteroids (mroe than 10 mg prednisone/day or equivalent)
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

intervention Names
Drug: Doxil, melphalan, bortezomib
label
Doxil® + Melphalan + Velcade (DMV)
type
EXPERIMENTAL

interventions

arm Group Labels
Doxil® + Melphalan + Velcade (DMV)
description
Doxil®: IV over 30-60 min, Day 1 q28d Melphalan: IV over 30 min, Day 1 q28d Velcade®: IV bolus, Day 1, 4, 8, 11 q28d Dose Level 1: Doxil 10 mg/m2, Melphalan 5 mg/m2, Velcade 0.7 mg/m2 Dose Level 2: Doxil 10 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2 Dose Level 3: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2 Dose Level 4: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 1.0 mg/m2
name
Doxil, melphalan, bortezomib
other Names
Doxil, melphalan, Velcade
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 13
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Safety assessments will be evaluated as the proportion of patients experiencing the following: treatment-related grade 3 or higher toxicity (hematologic and nonhematologic) and treatment-related death.
measure
Number of Participants With Dose Limiting Toxicities (DLT) (Phase 1)
time Frame
Up to 2 cycles of treatment, approximately 56 days
description
The MTD will be considered the dose below where \<= 3 patients experience a DLT and the dose that two cycles can be given without meeting toxicity criteria.
measure
Maximum Tolerated Dose (MTD) (Phase 1)
time Frame
Up to 1 year

secondary Outcomes

description
NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3 will be used to determine all treatment related toxicities at the MTD. Participants entered at the MTD Dose level from the phase I portion of the study will also be included in this analysis
measure
Number of All Treatment-related Toxicities at the MTD (Phase 1)
time Frame
5 years
description
At each cycle, participants will be assessed for treatment response: Complete Response (CR), Near CR(nCR), Partial Response (PR), Minimal Response (MR), Stable Disease (SD), or Progressive Disease (PD) on at least 2 measurements at minimum of a 4 week interval. The overall response rate will use the best response of CR, nCR, PR, MR, or SD. In order to qualify for responses, the following events may NOT have occurred - new/increased size of plasmacytomas or bone lesions, recurrence or persistence of hypercalcemia. Collapse of bony structure from previous disease will not constitute progression or failure to respond. Participants entered at the MTD Dose level from the phase I portion of the study will also be included in this analysis
measure
Overall Response Rate
time Frame
Up to 5 years
description
Efficacy of DMV as determined by time to first observed response. Participants entered at the MTD Dose level from the phase I portion of the study will also be included in this analysis
measure
Time to Response (Phase 2)
time Frame
28 days
description
Efficacy of DMV as determined by progression free survival. Participants entered at the MTD Dose level from the phase I portion of the study will also be included in this analysis
measure
Progression-free Survival (Phase 2)
time Frame
Up to 5 years
description
Overall survival is defined as the amount of time from start of study therapy until death, or study completion. Participants entered at the MTD Dose level from the phase I portion of the study will also be included in this analysis
measure
Overall Survival (Phase 2)
time Frame
Up to 5 years

Full study description

brief Summary: The median overall survival (OS) of relapsed/refractory multiple myeloma (MM) is less than nine months. However, phase II data with the proteasome inhibitor bortezomib (Velcade®) has been heartening, with 35% overall response rates and median survival of 16 months. In-vitro data has shown that this agent dramatically increases the sensitivity to chemotherapeutic agents. Liposomal doxorubicin (Doxil), melphalan, and bortezomib all have different mechanisms of action and toxicity profiles. Clinical studies employing two drug combinations with these agents in patients with refractory MM have found favorable efficacy (nearly no progression of disease) and tolerance data. Thus, the investigators are initiating a phase I/II study to examine the safety and efficacy of combining all three agents into the regimen DMV (Doxil® + melphalan + Velcade).
detailed Description: Dose Level 1: Doxil 10 mg/m2, Melphalan 5 mg/m2, Velcade 0.7 mg/m2 Dose Level 2: Doxil 10 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2 Dose Level 3: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2 Dose Level 4: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 1.0 mg/m2 Adjunctive therapy with a bisphosphonate, either pamidronate or zoledronic acid, will be given monthly. Dose Escalation Schedule: Dose escalation will occur only after patients have completed at least two cycles at a given dose level. 1. If 0/3 experience DLT (as defined in attachment Section 6.0), the next three patients will be escalated by one dose level. 2. If 1/3 experience DLT, 3 additional patients enrolled at this dose level. * If 0, 1, or 2 of these additional patients experience DLT (i.e. total 3/6), the dose will be escalated. * If 3/3 experience DLT (i.e. total 4/6) then the next lower dose will be considered the MTD.. 3. If 2/3 experience DLT, 3 additional patients enrolled at this dose level. * If 0 or 1 of these additional patients experience DLT (i.e. total 3/6), the dose will be escalated. * If 2 or more/3 experience DLT (i.e. total more than 3/6) then the next lower dose level is MTD

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-c7ddd4da0963ebd4358f
requested nct id
NCT00985907
primary nct id
NCT00985907
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true&pageToken=ZVt07cGHkvI2wRk2CJf6_LLtzoHfMpVrd7KrgP4ZmziVu_Q-IQ
source record id
Source null
source file sha256
f61b5b8281f834a98709317598003056a2aa82c9b92a292e3623f400c9c3291b
payload sha256
10e6bf744edd61b13437e1af91db88d8f23dcb276d1ee3869f38268c3c5d0ed2
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-c7ddd4da0963ebd4358f
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00985907
occurrences
context exact
NCT00985907
end
11
exact text
NCT00985907
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-001.json
source file sha256
f61b5b8281f834a98709317598003056a2aa82c9b92a292e3623f400c9c3291b
source json pointer
/studies/64/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
4e600410c94fa4549feb28367e1ab9fd64db1d0bd53c21c0f29e05fa3a8b36d7
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true&pageToken=ZVt07cGHkvI2wRk2CJf6_LLtzoHfMpVrd7KrgP4ZmziVu_Q-IQ

Preserved source evidence · Not medical advice